Cabozantinib (targets: VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, TIE2, AXL) and Axitinib (targets: PDGFR, KIT, VEGFR) are common target drug for ccRCC. This evidence concerns the gene FLT1 and nonpapillary renal cell carcinoma.